Beta Bionics Announces Participation at Upcoming Investor Conferences

About this update from Beta Bionics, Inc.

IRVINE, Calif. , Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time): Wolfe Research 7th Annual Healthcare Conference on Tuesday, November 18, 2025 at 2:00pm Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30pm The presentations will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com , and will be archived there for future replay following the events. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com . Investor Relations: Blake Beber Head of Investor Relations [email protected] Media and Public Relations : Karen Hynes Vice President of Marketing [email protected] Source: Beta Bionics, Inc. Source: Beta Bionics, Inc.

View stock analysis, news, and events for Beta Bionics, Inc.